Search research articles
Contact Us
Filters
Showing results (91-100 of 171) with videos related to
Page
of 18
Sort By:
Geburtshilfe Und Frauenheilkunde
|
October 29, 2019
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
Manfred Welslau, Andreas D Hartkopf, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde
|
December 1, 2018
Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Volkmar Müller, Achim Wöckel, Michael P Lux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner, Michael Untch, Carsten Denkert, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years
Berit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Oncology Research and Treatment
|
May 14, 2015
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Christian M Kurbacher, Thomas Fietz, Ingo J Diel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Geburtshilfe Und Frauenheilkunde
|
June 1, 2019
Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Hans-Christian Kolberg, Andreas Schneeweiss, Tanja N Fehm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Andreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Oncotarget
|
September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Gunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 171) with videos related to
Sort By:
Page
of 18
Geburtshilfe Und Frauenheilkunde
|
October 29, 2019
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
Manfred Welslau, Andreas D Hartkopf, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde
|
December 1, 2018
Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Volkmar Müller, Achim Wöckel, Michael P Lux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner, Michael Untch, Carsten Denkert, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years
Berit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Oncology Research and Treatment
|
May 14, 2015
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
Christian M Kurbacher, Thomas Fietz, Ingo J Diel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Geburtshilfe Und Frauenheilkunde
|
June 1, 2019
Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Hans-Christian Kolberg, Andreas Schneeweiss, Tanja N Fehm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Andreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Oncotarget
|
September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Gunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Page
of 18